COVID-19 - Collection of articles on the Coronavirus outbreak
23 December 2020
Vol. 90 No. 4 (2020)
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1839
Views
920
Downloads
Authors
We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.
Altmetrics
Downloads
Download data is not yet available.
Citations
How to Cite
“SARS-CoV-2 Related Pneumonia in an Adult With Cystic Fibrosis: Natural Favourable Clinical Course or Effective Therapy?”. 2020. Monaldi Archives for Chest Disease 90 (4). https://doi.org/10.4081/monaldi.2020.1579.